A11100P

N6-benzoil-2'-deoxi-5'-O-(4,4'-dimetoxitritil)adenosina 3'-(2-cianoetil diisopropilfosforamidita)

• Sinónimos: DMT-dA(bz) Pharmadite^®
• Fórmula empírica (notación de Hill): C₄₇H₅₂N₇O₇P
• Número de CAS: 98796-53-3
• Peso molecular: 857.93
• Número MDL: MFCD00036314
• Código UNSPSC: 41116107
• ID de la sustancia en PubChem: 329770659
• NACRES: NA.51

Propiedades

• origen biológico: non-animal source (no BSE/TSE risk)
• Nivel de calidad: 300
• tpo: for DNA synthesis
• Línea del producto: Proligo Reagents
• Ensayo: ≥99.5% (reversed phase HPLC); >99.5% (³¹P-NMR)
• Formulario: powder or granules
• técnicas: oligo synthesis: suitable
• impurezas: >= 170ppm, none detected (S/N <2.5); ≤0.1% P(III) 100-169ppm (³¹P-NMR); ≤0.1% single unspecified Imprity (reversed phase HPLC); ≤0.3% dA2 (reversed phase HPLC, DMT-dA(bz) cyanoethyl-H-posphonate); ≤0.3% dA3 (reversed phase HPLC, DMT-dA(bz) phosphoramidate); ≤0.30 wt. % water content (Karl Fischer); ≤0.5% P(V) -25-99ppm (³¹P-NMR); ≤3.0 wt. % residual solvent content
• color: white to off-white
• solubilidad: soluble, clear
• idoneidad: conforms to structure for H-NMR; conforms to structure for LC-MS
• perfil del nucleósido: base: deoxyadenosine; base protecting group: benzoyl; 2' protecting group: none; 5' protecting group: DMT; deprotection: standard
• temp. de almacenamiento: 2-8°C
• cadena SMILES: COc1ccc(cc1)C(OC[C@H]2O[C@H](C[C@@H]2OP(OCCC#N)N(C(C)C)C(C)C)n3cnc4c(NC(=O)c5ccccc5)ncnc34)(c6ccccc6)c7ccc(OC)cc7
• InChI: 1S/C47H52N7O7P/c1-32(2)54(33(3)4)62(59-27-13-26-48)61-40-28-42(53-31-51-43-44(49-30-50-45(43)53)52-46(55)34-14-9-7-10-15-34)60-41(40)29-58-47(35-16-11-8-12-17-35,36-18-22-38(56-5)23-19-36)37-20-24-39(57-6)25-21-37/h7-12,14-25,30-33,40-42H,13,27-29H2,1-6H3,(H,49,50,52,55)/t40-,41+,42+,62?/m0/s1
• Clave InChI: GGDNKEQZFSTIMJ-AKWFTNRHSA-N

Descripción

Descripción general

DMT-dA(bz) Pharmadite^® is a Pharmadite^® product line that represents a new class of standard protected DNA phosphoramidites that are designed with highly controlled impurity profiles and exceptional overall purity. Pharmadite phosphoramidites are characterized by their exceptional purity and well-defined impurity profile. In particular, they are essentially free from contaminants that interfere in coupling reactions, such as other nucleosidic or non-nucleosidic phosphoramidites (P(III)-contaminants). All remaining impurities in Pharmadite phosphopramidites, if present, are identified, characterized, and quantified. The impact of any such defined impurities on the synthesis of oligonucleotides is well understood and has been shown to be insignificant.

Aplicación

Pharmadite products fulfill all requirements of starting materials for themanufacture of active pharmaceutical ingredients as defined in the EMEA "Note for guidance on the chemistry of the new active substance," making them suitable building blocks for oligonucleotide drugs.

Otras notas

Pharmadite phosphoramidites are manufactured in scales of up to multi-hundred kilos, under certified ISO 9001 quality systems.

Información legal

Pharmadite is a registered trademark of Merck KGaA, Darmstadt, Germany

Información de seguridad

• Código de clase de almacenamiento: 11 - Combustible Solids
• Clase de riesgo para el agua (WGK): WGK 3
• Punto de inflamabilidad (°F): Not applicable
• Punto de inflamabilidad (°C): Not applicable